The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on novel therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." https://deannafrvy620417.tribunablog.com/high-stakeholder-pharma-the-speculative-wager-54631710